Marcus Capital LLC decreased its stake in Pfizer Inc. (NYSE:PFE) by 5.9% during the second quarter, Holdings Channel reports. The fund owned 6,400 shares of the biopharmaceutical company’s stock after selling 400 shares during the period. Marcus Capital LLC’s holdings in Pfizer were worth $225,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Catamount Wealth Management raised its position in Pfizer by 14.2% in the first quarter. Catamount Wealth Management now owns 4,395 shares of the biopharmaceutical company’s stock valued at $130,000 after buying an additional 545 shares during the last quarter. Stuart Chaussee & Associates Inc. raised its position in Pfizer by 64.3% in the second quarter. Stuart Chaussee & Associates Inc. now owns 5,430 shares of the biopharmaceutical company’s stock valued at $193,000 after buying an additional 2,125 shares during the last quarter. Financial Strategy Network LLC purchased a new position in Pfizer during the first quarter valued at $205,000. Oakmont Partners LLC purchased a new position in Pfizer during the second quarter valued at $211,000. Finally, Arete Wealth Advisors LLC raised its position in Pfizer by 11.3% in the first quarter. Arete Wealth Advisors LLC now owns 7,172 shares of the biopharmaceutical company’s stock valued at $213,000 after buying an additional 726 shares during the last quarter. 69.66% of the stock is currently owned by institutional investors and hedge funds.
Pfizer Inc. (NYSE:PFE) traded down 0.18% on Wednesday, hitting $33.07. The stock had a trading volume of 15,138,664 shares. Pfizer Inc. has a 1-year low of $28.25 and a 1-year high of $37.39. The company has a 50-day moving average price of $34.20 and a 200-day moving average price of $34.27. The stock has a market capitalization of $200.59 billion, a price-to-earnings ratio of 29.32 and a beta of 0.86.
Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, August 2nd. The biopharmaceutical company reported $0.64 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.62 by $0.02. The firm earned $13.10 billion during the quarter, compared to the consensus estimate of $13.01 billion. Pfizer had a return on equity of 23.37% and a net margin of 14.88%. The company’s revenue for the quarter was up 10.9% on a year-over-year basis. During the same quarter last year, the company posted $0.56 EPS. Equities analysts predict that Pfizer Inc. will post $2.46 earnings per share for the current year.
The company also recently disclosed a quarterly dividend, which will be paid on Thursday, December 1st. Investors of record on Friday, November 11th will be issued a dividend of $0.30 per share. The ex-dividend date is Tuesday, November 8th. This represents a $1.20 dividend on an annualized basis and a dividend yield of 3.63%. Pfizer’s dividend payout ratio is 95.24%.
PFE has been the topic of several recent analyst reports. Jefferies Group reduced their price objective on shares of Pfizer from $42.00 to $40.00 and set a “buy” rating on the stock in a research note on Monday, June 20th. Deutsche Bank AG restated a “buy” rating on shares of Pfizer in a report on Wednesday, June 15th. Vetr downgraded shares of Pfizer from a “strong-buy” rating to a “buy” rating and set a $37.28 target price on the stock. in a report on Tuesday, June 28th. Piper Jaffray Cos. set a $54.00 target price on shares of Pfizer and gave the stock a “buy” rating in a report on Monday, July 25th. Finally, JPMorgan Chase & Co. set a $40.00 target price on shares of Pfizer and gave the stock a “buy” rating in a report on Monday, July 25th. Ten analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has issued a strong buy rating to the company. The company presently has an average rating of “Buy” and an average target price of $38.78.
Pfizer Inc is a research-based global biopharmaceutical company. The Company is engaged in discovering, developing and manufacturing of healthcare products. Its portfolio includes medicines, vaccines and medical devices, as well as consumer healthcare products. Its products include Prevnar/Prevenar 13, Lyrica, Enbrel, Lipitor, Viagra, Sutent, BeneFIX, Genotropin, ReFacto, Xyntha and Enbrel.